Measurement of the Oxygen Saturation in the Retinal Vessels With Oxymap
1 other identifier
observational
300
1 country
1
Brief Summary
Retinal oximetry can be measured with newly developed Oxymap (Oxymap ehf, Reykjavik, Iceland). Briefly, the device simultaneously acquires digital images at two wavelengths and automatically tracks retinal vessels on both images. Retinal vessel oxygen saturation is estimated by spectrophotometric analysis of light reflected from retinal vessels and from the immediately surrounding retina. Oxygen saturation measurements are made on major temporal arteries and veins. Briefly, the first and second degree vessels are used, with the addition of third degree vessels in images where peripapillary haemorrhage prevented analysis close to the optic disc. Vessel segments chosen for analysis are used consistently for consecutive measurements in the same retina.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2014
CompletedFirst Submitted
Initial submission to the registry
December 12, 2014
CompletedFirst Posted
Study publicly available on registry
December 17, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2018
CompletedMarch 7, 2018
March 1, 2018
4 years
December 12, 2014
March 6, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change of retinal oxygen saturation from baseline at 6 months
Six months.
Interventions
Retinal oximetry will be performed with Oxymap.
Eligibility Criteria
Healthy eyes and eyes with various chorioretinal disease.
You may qualify if:
- Healthy eyes and eyes with various chorioretinal diseases, including diabetic retinopathy, retinal vein occlusion, epiretinal membrane, macular hole, inherited chorioretinal diseases, glaucoma, retinal detachment, etc.
You may not qualify if:
- Eye with medial opacity.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kagawa University Faculty of Medicine
Hiragi, Kagawa-ken, 761-0793, Japan
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
AKITAKA TSUJIKAWA, MD
Kagawa Univerisity Faculty of Medicine
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor and Chairman
Study Record Dates
First Submitted
December 12, 2014
First Posted
December 17, 2014
Study Start
December 1, 2014
Primary Completion
December 1, 2018
Study Completion
December 1, 2018
Last Updated
March 7, 2018
Record last verified: 2018-03